www.chiesigroup.com Guest

The affiliate achieved excellent performance: turnover increased by 20% as a result of the successful launches of Foster and Bramitob and the consolidation of Artedil sales.

These results made corporate products surpass the 50% mark for all company sales.

The main goals for the current year are based on the further growth of respiratory and cardiovascular products and the launch of the new anti-hypertensive combination, Vivace. To reach these goals more effectively, the company reorganised into business units: one is dedicated to the Primary Care market, and the other to the Special Care market.